PATENT CLAIM ANALYSIS

Application Number: 15747218
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "249000"]

Abstract:
Disclosed is a compound of Formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein one R 3  is H and the other R 3  is an aryl group substituted with zero to 3 R 3a ; and R 1 , R 2 , and R 3a  are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors for the inhibition or prevention of platelet aggregation, and the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder. Also disclosed are methods of using such compounds for the treatment of human papillomavirus. Additionally, pharmaceutical compositions comprising at least one compound of Formula (I) are disclosed.

Claim (Index 7):
The pharmaceutical composition according to  claim 6  wherein:\n R 1  is \u2014OCHF 2 ; \n R 2  is Cl, Br, \u2014CN, \u2014CH 3 , \u2014CF 3 , \u2014CH\u2550CH 2 , \u2014C\u2261CH, or \u2014C(O)OCH 3 ; \n R 3  is phenyl or naphthalenyl substituted with 1 or 2 R 3a ; and \n R 3a , at each occurrence, is independently F, Cl, Br, \u2014CH 3 , \u2014CF 3 , \u2014OCH 3 , or \u2014OCF 3 .

Metadata:
- Claim Count in Document: 18.0
- Percentile: 86.0
- Lexical Diversity: 1.86957
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14747037', '14746908', '15549257', '15549307', '14396807']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7976590051967478
- 35 USC 102 Novelty (BERT): 0.5125358233405978
- Combined Prediction Score: 0.7691466870111328
- Mean Citation Score: 293.59795
- Max Citation Score: 300.1764
- Similarity Product: 234.222516297698

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test